1RCTn=70 · small study2013
In a randomized, double-blind, placebo-controlled trial, 300 mg/day of Mekabu fucoidan raised post-vaccination antibody titers in elderly adults — fucoidan's single strongest human result.
Negishi H, Mori M, Mori H, Yamori Y · J Nutr (2013)
- Randomized, double-blind, placebo-controlled trial in 70 volunteers over age 60
- Mekabu fucoidan 300 mg/day for 4 weeks before vaccination produced higher antibody titers against all three influenza strains than placebo
- The fucoidan group met EU licensure criteria for the B strain (geometric mean titer ratio 2.4) where placebo did not (1.7); NK-cell activity tended to rise